title: Cyclin E, p27 and mutant p53 do not predict the prognosis in AJCC stage II colorectal carcinomas.
abstract: OBJECTIVE
  Carcinogenesis is characterized by the abnormal regulation of cell cycle. The abnormal expression of the regulators of cell cycle may be related to the prognosis. Since the clinical significance of the expression of the three proteins in colorectal carcinomas is still controversial, we evaluated the prognostic value of the expression of cyclin E, p27 and mutant p53 in stage II colorectal cancer.
  
  
  METHODS
  The expression levels of cyclin E, p27 and mutant p53 proteins in 41 patients with stage II colorectal carcinomas were analyzed by immunohistochemistry.
  
  
  RESULTS
  In the univariate analysis, the level of CEA at diagnosis was associated with disease relapse. In the multivariate analysis, the clinicopathological variables such as age, gender, site of primary tumor, tumor size, state of tumor differentiation and preoperative plasma CEA level were not associated with disease relapse. When Kaplan-Meier survival curves were constructed to determine the prognosis, cyclin E, p27 and mutant p53 expressions did not predict poor prognosis.
  
  
  CONCLUSIONS
  Our results suggested that the expression of cyclin E, p27 and mutant p53 proteins did not predict the clinical outcome in the stage II colorectal carcinomas.
authors.affiliation: Department of Internal Medicine, Sungkyunkwan University School of Medicine, Center for Health Promotion, Samsung Medical Center, Seoul 135-710, Korea.
authors.forename: Yun Jeong
authors.initials: YJ
authors.lastname: Lim
authors.forename: Young-Ho
authors.initials: YH
authors.lastname: Kim
authors.forename: Geung Hwan
authors.initials: GH
authors.lastname: Ahn
authors.forename: Ho Kwung
authors.initials: HK
authors.lastname: Chun
authors.forename: Woo Young
authors.initials: WY
authors.lastname: Jang
authors.forename: Jun Haeng
authors.initials: JH
authors.lastname: Lee
authors.forename: Hee Jung
authors.initials: HJ
authors.lastname: Son
authors.forename: Poong-Lyul
authors.initials: PL
authors.lastname: Rhee
authors.forename: Jae J
authors.initials: JJ
authors.lastname: Kim
authors.forename: Seung Woon
authors.initials: SW
authors.lastname: Paik
authors.forename: Byung Chul
authors.initials: BC
authors.lastname: Yoo
authors.forename: Jong Chul
authors.initials: JC
authors.lastname: Rhee
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D018797:Cell Cycle Proteins / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D019927:Cyclin E / Q000032:analysis*; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000032:analysis*
chemical_list: D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; D019927:Cyclin E; D016159:Tumor Suppressor Protein p53; D025521:Tumor Suppressor Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27